Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall… read more.
Diagnosing infectious conditions can be challenging. Diagnosis is especially challenging for uncommon and emerging infectious diseases for which there’s limited clinical experience. Nevertheless, successfully identifying patients with infectious… read more.
Otsuka Pharmaceutical, Co. Ltd. and Click Therapeutics, Inc., announce that the FDA has cleared Rejoyn (developed as CT-152), the first prescription digital therapeutic authorized in the U.S. for… read more.
Following federal approval for over the counter emergency contraception in 2006, emergency departments across the U.S. saw dramatic decreases in related visits and medical charges, a new study… read more.
Vanda Pharmaceuticals Inc announced that the FDA has approved Fanapt (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults…. read more.
CStone Pharmaceuticals announced that the National Medical Products Administration (NMPA) of China has approved the supplemental biologics license application (sBLA) for sugemalimab (Cejemly) in combination with fluoropyrimidine- and… read more.
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in Japan for the treatment of adult patients with unresectable or recurrent PIK3CA, AKT1, or PTEN-altered hormone… read more.
Individuals with heart disease stand to gain the most from a low-sodium diet but, on average, consume over twice the recommended daily sodium intake, according to a study… read more.
CSL Behring, announced survey results showing that the majority of surveyed people living with chronic inflammatory demyelinating polyneuropathy (CIDP) agree they are interested in exploring more convenient treatment… read more.
Researchers from Fred Hutchinson Cancer Center, the American Cancer Society Cancer Action Network and peer institutions released new findings in the Journal of Clinical Oncology showing that when… read more.
UCB Canada Inc. is pleased to announce that Bimzelx (bimekizumab injection) has received authorization from Health Canada for two new indications. On February 23, 2024, BImzelx was approved… read more.
The lack of persistence in home physiotherapy exercises is a well-known problem hindering the effectiveness of treatment. It is especially evident in vestibular rehabilitation (exercises to treat dizziness… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
